Kinder Morgan (KMI) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Dell Technologies (DELL) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

KB Home (KBH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Arista Networks (ANET) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Recently, Zacks.com users have been paying close attention to SoundHound AI (SOUN). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to Nvidia (NVDA). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to DocuSign (DOCU). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to Fortinet (FTNT). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to Costco (COST). This makes it worthwhile to examine what the stock has in store.

Zacks.com users have recently been watching TSMC (TSM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks.com users have recently been watching GigaCloud Technology Inc. (GCT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

ENGLEWOOD, Colo. , Aug. 1, 2025 /PRNewswire/ -- WOW!

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025. The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models.

Apple (AAPL) posted record June quarter revenue as iPhone sales topped Wall Street estimates. Jenny Horne goes under the hood on the Mag 7 earnings report, highlighting a record-high services segment revenue number.

BEP's second-quarter 2025 earnings and revenues improve year over year. Funds From Operations rise 10%.

Taco Bell, KFC and digital upgrades are expected to fuel YUM! Brands' second-quarter results, with EPS rising 7.4% year over year.

FSLR tops Q2 earnings and sales estimates, narrows 2025 EPS range and raises full-year revenue and shipment outlook.

AM's Q2 earnings and revenues gain on increased gathering volumes, fee growth and improved freshwater delivery performance.

Marcus (MCS) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to a loss of $0.17 per share a year ago.